Navigation Links
DEET in Bug Spray Tied to Neural Damage in Mice
Date:8/5/2009

More research needed to see if compound has same effect in humans, experts say

WEDNESDAY, Aug. 5 (HealthDay News) -- New French research suggests the main ingredient used in many insect repellants may affect the central nervous system, at least in mice.

And combining this ingredient -- DEET (N,N-Diethyl-3-methylbenzamide) -- with carbamates, a type of pesticide that is often used with DEET, compounded the effects.

Although the authors, publishing online Aug. 5 in BMC Biology, warn of potential dangers to humans, they also acknowledge the need for more studies on the subject.

Meanwhile, people should probably worry more about the health risks from mosquitoes and other insects than about the potential harms of DEET, experts said.

"This work was done primarily in test tubes in order to try to understand some of the mechanisms," said Dr. Ted Schettler, science director of the Science & Environmental Health Network. "The mechanistic information is very useful but the jury is still out on what implications this has for humans."

"DEET has been used for a very long time with very few bad outcomes," added Susan Paskewitz, a professor of entomology at the University of Wisconsin, Madison. "People have killed themselves by drinking it, but you can do that with alcohol or salt. And a few have had neurological symptoms after application for long periods and high doses."

As for the combination of DEET and carbamates, Paskewitz added, "if there are the kinds of synergies suggested by the study, they aren't happening very often. I also would guess that the actual concentration in the body is much lower than they had to use in the study to see an effect in the mouse tissues."

But by better understanding the mechanisms by which DEET works, scientists may be able to come up with better repellant products, said Paul Sanberg, distinguished professor of neurosurgery and director of the
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product
2. Winnipeg Veterinary Company Pharm-Vet Produces Essential Oil-Infused Mosquito Spray Thats a Welcome and Safe Alternative to Controversial Deet-Based Repellants
3. Ocean Spray Teams Up With the American Heart Associations Go Red For Women and Its Go Red BetterU Program
4. Coming Soon: Lung-Cancer Spray?
5. New Spray Could Benefit Cystic Fibrosis Patients
6. Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
7. Groundbreaking First Response Spray Now Available in Europe
8. Topical Spray Helped Men With Premature Ejaculation
9. Premature ejaculation spray enables men to last 6 times longer after penetration
10. Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical
11. CSA Medical, Inc. Announces Launch of New Web Site for Spray Cryotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DEET in Bug Spray Tied to Neural Damage in Mice
DEET in Bug Spray Tied to Neural Damage in Mice
Breaking Medicine News(10 mins):Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 1Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 2Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 3Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 1Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 1Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 3
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7